Iqvia (NYSE:IQV) Given New Price Target at Piper Sandler

Iqvia (NYSE:IQV) had its target price boosted by Piper Sandler from to in a research report released on Thursday morning, The Fly reports.

IQV has been the subject of a number of other research reports. Wolfe Research raised Iqvia from a peer perform rating to an outperform rating in a research report on Thursday, November 14th. Cfra raised Iqvia from a hold rating to a buy rating and lifted their price objective for the company from $148.00 to $185.00 in a research report on Wednesday. UBS Group lifted their price objective on Iqvia from $187.00 to $200.00 and gave the company a buy rating in a research report on Thursday. JPMorgan Chase & Co. lifted their price objective on Iqvia from $180.00 to $195.00 and gave the company an overweight rating in a research report on Thursday. Finally, Credit Suisse Group reissued a buy rating and set a $170.00 price objective on shares of Iqvia in a research report on Friday, December 20th. One analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $174.30.

IQV traded down $1.47 during trading on Thursday, reaching $164.32. 2,962,308 shares of the stock traded hands, compared to its average volume of 1,312,776. The stock has a market cap of $31.03 billion, a price-to-earnings ratio of 134.69, a price-to-earnings-growth ratio of 1.70 and a beta of 0.91. Iqvia has a fifty-two week low of $130.77 and a fifty-two week high of $169.14. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.12 and a quick ratio of 1.12. The stock’s 50-day simple moving average is $157.99 and its two-hundred day simple moving average is $151.69.

Iqvia (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 12th. The medical research company reported $1.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. The firm had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.85 billion. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.50 earnings per share. Research analysts anticipate that Iqvia will post 5.9 earnings per share for the current fiscal year.

In other news, CFO Michael R. Mcdonnell sold 12,000 shares of Iqvia stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $155.07, for a total value of $1,860,840.00. Following the transaction, the chief financial officer now directly owns 14,366 shares in the company, valued at $2,227,735.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael J. Evanisko sold 6,250 shares of Iqvia stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $160.08, for a total value of $1,000,500.00. The disclosure for this sale can be found here. Insiders sold 37,000 shares of company stock valued at $5,830,215 in the last ninety days. Insiders own 6.00% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Penserra Capital Management LLC increased its stake in shares of Iqvia by 57.5% in the fourth quarter. Penserra Capital Management LLC now owns 189 shares of the medical research company’s stock worth $29,000 after purchasing an additional 69 shares during the period. Usca Ria LLC bought a new position in shares of Iqvia in the third quarter worth about $29,000. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Iqvia by 379.5% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 211 shares of the medical research company’s stock worth $33,000 after purchasing an additional 167 shares during the period. Evolution Wealth Advisors LLC increased its stake in shares of Iqvia by 303.6% in the fourth quarter. Evolution Wealth Advisors LLC now owns 222 shares of the medical research company’s stock worth $34,000 after purchasing an additional 167 shares during the period. Finally, Citizens Financial Group Inc RI bought a new position in shares of Iqvia in the fourth quarter worth about $34,000. Institutional investors and hedge funds own 89.93% of the company’s stock.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Article: What does RSI mean?

The Fly

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.